A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...
Biobeat Technologies has raised $50 million in a series B round to help boost the commercialization of its blood pressure ...
The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...
In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback